Brief: Tarsus Announces Positive Topline Data From Phase 1B Trial Evaluating TP-05 For The Prevention Of Lyme Disease
15/12/2022 15:16
Dec 15 (Reuters) - Tarsus Pharmaceuticals Inc TARS.O :
* TARSUS ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 1B
CALLISTO
TRIAL AND INITIATES PHASE 2A CARPO HUMAN TICK KILL TRIAL
EVALUATING TP-05, A NOVEL, ORAL THERAPEUTIC FOR THE PREVENTION
OF LYME DISEASE
* TARSUS PHARMACEUTICALS INC- POSITIVE PHASE 1B CALLISTO
DATA
SHOWS THAT TP-05 IS WELL TOLERATED AND SAFETY DATA SUPPORTS
PROGRESSION TO PHASE 2A
Source text for Eikon: ID:nGNX6tp1tX
Further company coverage: TARS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tarsus Pharmaceuticals
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Tarsus Pharmaceuticals Files For Offering Of Up To 2.91 Million Shares Of Common Stock By Selling Stockholders
U.S. RESEARCH ROUNDUP-Argan, Mastec, Oracle
Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition (updated)